▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] The US FDA’s advisory committee has approved advancing the application of Celltrion's CT-P10, a copy version to Roche’s blockbuster cancer drug Rituxan, the Korean biopharmaceutical...
[THE INVESTOR] DAYLI Partners CEO Lee Seung-ho reckons a sea change in the local biotechnology industry and is gearing up to reap huge profits from the fast-growing segment. “I haven’t seen this ki...
[THE INVESTOR] Merck, a global health care company, has won a US$117 million contract to supply the biosimilar Renflexis, developed by Samsung Bioepis, to the US Department of Veterans Affairs, indu...
[THE INVESTOR] Korean drug firm Chong Kun Dang Pharmaceutical said on Oct. 5 that it sought approval for sales of its anemia biosimilar in Japan from health authorities there earlier this week. ...
[THE INVESTOR] Korean pharmaceutical firm Dong-A ST said on Oct. 1 its co-developer Sanwa Kagaku Kenkyusho has sought approval from the Japanese health regulator for its biosimilar version of Amgen’...
[THE INVESTOR] Samsung BioLogics , Korea’s biopharmaceutical contract development and manufacturing organization said on Oct. 1 that its third plant -- the world’s largest single bio manufacturing ...
[THE INVESTOR] Samsung Bioepis said on Sept. 27 that the US Food and Drug Administration has accepted its application to review SB5, its biosimilar candidate referencing US drug maker AbbVie’s Humir...
[THE INVESTOR] The financial regulator said on Sept. 19 it will allow biotechnology and pharmaceutical firms to voluntarily restate accounting errors amid a lack of clear supervisory rules on the in...
[THE INVESTOR] Celltrion said Sept. 16 that the US Food and Drug Administration has given its OK to the Korean biopharmaceutical firm’s manufacturing facility after re-inspection, clearing a year-l...
[THE INVESTOR] Korean pharmaceutical and bio companies have seen their share prices surge about 20 percent recently on eased concerns over accounting regulations and other positive factors, data sho...
[THE INVESTOR] Olix , Korea’s RNA-interference drug developer, said on Sept. 17 it has tapped former Boston Biomedical executive Wei Li to lead its new entity in the US. Li has been appointed as C...
[THE INVESTOR] Allergan has confirmed it will soon begin pivotal phase 3 clinical trials of a liquid-type botulinum toxin it licensed from Korean biotech Medytox with hopes to get US marketing app...
[THE INVESTOR] Seoul-based Hana Pharm said on Sept. 14 it has priced its initial public offering at 26,000 won (US$23.25) per share to raise around 106.1 billion won. The shares are expected to sta...
[THE INVESTOR] The US Food and Drug Administration will hold an advisory committee meeting next month to gather opinions from experts on Celltrion 's CT-P10, a biosimilar referencing Roche’s blood...
[THE INVESTOR] GC Medical Science said Sept. 12 it has broken ground for a plant that will manufacture hemodialysis solutions. Covering an area of 22,000 square meters in Eumseong, North Chungcheon...
Samsung scouts AI startups in Paris
Overcoming Elliott hurdle, Hyundai heir tightens grip over W220tr empire
Jaguar Land Rover Korea introduces upgraded Velar
Korea widens tax evasion crackdown on ‘Seungri scandal’
Most LG businesses to fully adopt cloud services in 5 years: LG CNS
Samsung, Motorola compete to win 5G smartphone race
Amorepacific hosts yearly marathon for breast cancer awareness
BLACKPINK surpasses 20 mln YouTube subscribers
March 25, 2019
